Leveraging platinum-protein interactions to overcome chemoresistance

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Cancer cells often develop resistance to chemotherapy drugs like anthracyclines via efflux pumps.
• Platinum-based chemotherapy agents are less susceptible to efflux pumps due to their DNA and protein interactions.

Purpose of the Study:

• To design and evaluate novel dual warhead drug conjugates combining platinum and anthracycline functionalities.
• To assess the efficacy of these conjugates in overcoming chemoresistance and delaying drug resistance acquisition.

Main Methods:

• Synthesis of dual warhead drug conjugates by linking platinum pharmacophores to doxorubicin.
• In vitro and in vivo evaluation in a preclinical organoid-based model of metastatic colon cancer in mice.
• Mechanistic studies to elucidate the mode of action, including drug retention and subcellular distribution.

Main Results:

• The designed drug conjugates maintained anticancer activity similar to anthracyclines.
• Conjugates effectively circumvented drug efflux mechanisms and delayed the onset of chemoresistance.
• In vivo studies showed extended survival in metastatic colon cancer models.
• Mechanistic studies revealed improved drug retention and altered subcellular distribution due to platinum-protein interactions.

Conclusions:

• Dual warhead drug conjugates represent a promising strategy to overcome chemoresistance mediated by efflux pumps.
• The platinum-protein interaction mechanism offers a novel approach to enhance drug retention and efficacy.
• This approach holds potential for augmenting conventional chemotherapeutics and addressing resistance issues in cancer treatment.